Ravulizumab for aHUS patients
Treatments studied
Part of Blood & lymphatic, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests the drug ravulizumab for people with aHUS (a rare blood and kidney condition). It aims to see if the drug can help improve blood counts and kidney function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Weigh at least 20 kg (44 lbs).
- Have a clinical diagnosis of aHUS or a related condition (like infection, pregnancy, post-transplant, or high blood pressure crisis).
- Have all three signs: low platelets, low red blood cells (anemia), and acute kidney injury.
- Have not taken a complement inhibitor (like eculizumab) before.
- Agree to get a meningococcal vaccine and take antibiotics if needed.
- Start treatment within 14 days of the latest TMA episode.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well patients with aHUS in Poland are doing after treatment with ravulizumab (Ultomiris). It is for people who have already received this drug through the national program and agree to share their health information.
This study looks at how rare gene mutations may explain atypical HUS (aHUS) and how that could guide more personalized treatment. It mainly involves people who have had aHUS affecting blood counts and kidneys.
This is a registry that collects information from people diagnosed with atypical hemolytic uremic syndrome (aHUS). It helps researchers better understand the condition across different genetic causes and treatment needs.
This trial tests whether people with atypical hemolytic uremic syndrome (aHUS) who are doing well on anti-C5 treatment can safely switch to iptacopan. It focuses on both effectiveness (blood counts and kidney function) and safety after the switch.
This trial studies eculizumab, a targeted blood-clotting and immune system medicine, for adults hospitalized with hypertensive emergency–associated hemolytic uremic syndrome (a serious condition affecting kidneys and blood). It aims to see whether the drug can improve outcomes after this life-threatening event.
This study tests a drug called ravulizumab for children aged 2 to under 18 with IgA nephropathy, a kidney condition. It aims to see if the drug can help protect the kidneys and reduce protein in the urine.
Hear when a new Atypical Hemolytic Uremic Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.